A hair and scalp microbiome-friendly combination of enzymes

Abstract

The invention is related to specific enzyme combinations for use in the field of the hair and scalp care products.

Description

[0001] SkyLab AG 08.07.2025 A HAIR AND SCALP MICROBIOME-FRIENDLY COMBINATION OF ENZYMES FIELD OF INVENTION The present invention is related to the novel uses of chitinase with chitosanase and can be useful in hair care products. BACKGROUND OF INVENTION The human skin is inhabited by thousands of microorganisms, which form so-called “skin flora”. Microbiome means the genome of all microorganisms, both symbiotic and pathogenic, which interact with all types of cells in the organism [1]. Metabolic exchangesbetween the scalp surface and microbiome generally support symbiotic, commensal orpathogenic growth of microbial biofilms [2,3]. In the recent years a lot of scientific reports onthe studies of microbial population were published, in particularly, about scalp inhabitingbacteria and fungi [4-9]. Of note, Malassezia, Staphylococcus, Aspergillus, Pseudomonas spp.,etc., are the most important scalp pathogens

[0015] . The commensal can turn to causativepathogens, so none of the microorganisms can be considered as definitely beneficial. S.epidermidis and C. albicans are among the most thoroughly studied and well known examples

[0016] . As reported in the studies [10-13], P. acnes and S. epidermidis were found in the mainbacterial communities. In particular, in the scalp with dandruff P. acnes / S. epidermidis ratiowas found to be lower than in healthy scalp. Malassezia restricta and Malassezia globosaappeared to be the main fungal scalp colonizers, and lower M. restricta / M. globosa ratio wasassociated with a healthy scalp. Therefore, the dandruff scalp microbiome is characterized byhigher population of non-cultured Malassezia sp. compared to the healthy scalp

[0014] .Numerous antifungal systems are used for the treatment of fungal infections. For example, climbazole is one of the novel antifungal agents usually used in combination or as monotherapy. Climbazole affects normal functioning of the fungal cell wall leading to anti- fungal activity, however, this agent can cause local skin irritation manifested by the symptoms including redness, rash, and pruritus, and also allergic reactions

[0017] . Selenium sulfide eliminates excessive hair loss and irritation caused by the fungal scalp infection and reduces the cell adhesion in corneal layer. This agent possesses also local irritative, antibacterial, and light anti-fungal activities, which can contribute to its efficacy. Potential side effects include incidental greasiness or dryness of hair or scalp, greater hair loss, and scalp discoloration

[0018] . Piroctone olamine is used in shampoos due to its antifungal activity. This agent inhibits the degradation of sebum triglycerides to oleic and arachidonic acids. Side effects include irritation, edema, numbness, skin hemorrhage and shrinkage

[0019] . Zinc pyrithione is the most popular antifungal agent (active against the most commonscalp-inhabiting Malassezia species (Malassezia globosa и Malassezia restrica), which is usedas a component of various formulations for dandruff treatment. Despite many other systems zinc pyrithione is free of general side effects (though can cause harm upon ingestion)

[0017] . The efficacy depends on the targeted delivery of zinc pyrithione to the skin areas inhabited by these yeast species, including the scalp surface and the stalk of hair follicle

[0020] . Zinc pyrithioneinhibits the membrane transport processes and cell division in the fungal cell wall

[0021] . SinceMarch 1, 2022, the use of zinc pyrithione in the beauty products available in EU markets has been prohibited. The European Union decided to add this ingredient into the prohibited agent list because of its DNA-damaging effect. As is known the fungi of Malassezia spp. are the main causative agents of dandruff ofMalassezia genus.To date seven Malassezia species have been found and identified: M. furfur, M.sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and M. pachydermatis

[0028] .The fungal cell wall is composed of mannoproteins, chitin, and β-glucancs. Thomas Stalhberger et al.

[0036] reported that Malassezia species are ubiquitous residentsof human skin and are associated with several diseases such as seborrheic dermatitis, tinea versicolor, folliculitis, atopic dermatitis, and scalp conditions such as dandruff. Host-Malassezia interactions and mechanisms to evade local immune responses remain largelyunknown. Malassezia restricta is one of the most predominant yeasts of the healthy humanskin, Polysaccharides in the M. restricta cell wall are almost exclusively alkali-insoluble,showing that they play an essential role in the organization and rigidity of the M. restricta cellwall. Fractionation of cell wall polymers and carbohydrate analyses showed that thepolysaccharide core of the cell wall of M. restricta contained an average of 5% chitin, 20%chitosan, 5% β-(1.3)-glucan, and 70% β-(1.6)-glucan. In contrast to other yeasts, chitin andchitosan are relatively abundant, and β-(1.3)-glucans constitute a minor cell wall component. The most abundant polymer is β-(1.6)-glucans, which are large molecules composed of a linear β-(1.6)-glucan chains with β-(1.3)-glucosyl side chain with an average of 1 branch point every 3.8 glucose unit. Both β-glucans are cross-linked, forming a huge alkali-insoluble complex withchitin and chitosan polymers. M. restricta has a polysaccharide organization very different ofall fungal species analyzed to date. The average molecular mass of β-(1.6)-glucan chain about80 kDa (around 500 glucose units / chain). In contrast to most fungi analyzed, the polysaccharidecore of the M. restricta cell wall was extremely alkali-insoluble. HPLC and GLC analysis ofsugar composition showed that both AS and AI fractions were composed of glucose and glucosamine residues only, at 94 / 6 and 75 / 25 ratios, respectively, suggesting the presence of glucans and chitin / chitosan in the cell wall. To identify cell wall polysaccharides, specific enzymatic digestions were performed on the AI fraction. Recombinant endo-β-(1.3)-glucanase, endo-β-(1.6)-glucanase, chitosanase, and chitinase partially degraded the AI fraction, indicatingthe presence of β-(1.3)-glucan, β-(1.6)-glucan, chitin, and chitosan. M. restricta M. restricta isa commensal yeast of the skin microbiota. Under steady state conditions, Malassezia yeastsmanage to evade local immune responses and remain in balance with the human skin. Because fungal cell wall carbohydrates are widely conserved across the fungal kingdom, but absent in humans, these structural components of the cell wall are convenient targets for immune recognition and critical for host inflammation responses. β-(1.3)-Glucan recognition has been extensively studied as receptors have been identified in a number of human cells includingkeratinocytes (e.g. langerrin, dectin-1. CR3). In contrast, the effect of β-(1.6)-glucans on theimmune system has been poorly studied. Chitin is recognized by the immune system and particularly the keratinocytes. Chitin and chitosan were also activators of the human immune system, but their recognition and signaling pathways are totally independent. In addition, it has also been observed that large chitin fragments or the conversion of chitin to chitosan favors the escape from immune recognition. The characterization of the cell wall polysaccharides pavesthe way for a thorough understanding of the role of M. restricta polysaccharides (specially β-(1.6)-glucan or chitosan) in local immune response or in masking minor polysaccharides(e.g. β-(1.3)-glucan and chitin) from host recognition.Another species of Malassezia genus - M. furfur is a polymorphic lipophilicmicroorganism characterized by a thick, multilayer cell wall composed at an average of 5% of chitin, 20% of chitosan, 5% β-(1,3)-glucan and 70% of β-(1,6)-glucan

[0022] . It was shown that BuGH30 (glycosyl hydrolase degrades predominantly long-chain β-1-6 glucans with gentiobiose being a final product

[0023] . In addition, several enzymes related to chitin were found, namely, putative chitinases falling into GH 18 family, exochitinase in GH20 family and putativechitosanase in GH 75 family

[0024] . Chitosan can be enzymatically degraded by chitinases andchitosanases

[0025] .Chitinases are the enzymes degrading chitin. Chitinases are widely used, for instance,to produce pharmaceutically important chito-oligosaccharides and N-acetyl-D-glycosamine, asingle-cell protein, to isolate the protoplasts from fungi and yeast, and to control the fungal pathogens

[0026] . Chitinase is the most active at temperature 60°C amd pH=5,5 [DOI:10.21161 / mjm.44612]. Chitosanases are glycosyl hydrolases catalyzing the endohydrolysis of β-1,4-glycoside bonds in partially acetylated chitosan leading to release of the chitosan oligosaccharides. Chitosanases from various sources, mainly bacterial and fungal chitosanases, have been isolated, purified and characterized. Chitosanases became very attractive because of the broad range of potential uses as an advantageous agent for biocontrol of pathogenic fungi and insects, bioconversion of chitin biowastes resulted from the sea foods processing, etc.

[0027] . The optimal environmental conditions favoring the enzyme activity are 55℃ and pH 5 [Zhang, Q., Cao, H. Expression of chitosanase from Aspergillus fumigatus chitosanase in Saccharomyces cerevisiae by CRISPR-Cas9 tools. Bioresour. Bioprocess.11.20 (2024). DOI: 10.1186 / s40643-023-00718-4]. Chitosanase and chitinase partially degraded the cell wall of M. furfur. Enzymatic degradation by chitosanase resulted in solution of 75% of glucosamine and conversion of alkali- insoluble glucan fraction to water-soluble glucans

[0022] . Cellulase is an hydrolase catalyzing the cleavage of β(1,4)-glycosidic bonds in cellulose giving rise to glucose or cellobiose disaccharide. Cellulase degrades the cell wall component (cellulose) leading to release of biologically active compounds

[0029] . The highest efficacy is observed at 50-55℃ and pH 5.5 [DOI:10.2478 / mjhr-2019-0009]. Cellulases are exist as a multicomponent enzymatic system generally comprising three enzymes, which synergistically degrade the cellulose: endoglucanase, cellobiohydrolase and cellobiase (β-glucosidase). The first two enzymes work directly upon cellulose giving rise predominantly cellobiose and glucose as the reaction products, followed by glucose degradation by cellobiase

[0030] . β-D-mannanases are endohydrolases, which randomly cleave a backbone of 1,4-β-D- mannane galactomannane, glycomannane, galactoglucomannane, and mannane

[0031] , with the highest activity achieved at pH 6.0 and 65°C [DOI:10.1155 / 2016 / 6380147]. β-mannanase has a strong potential to be used in many industrial fields including feed, food, pharmaceutical and beauty industries

[0032] . Glucanases are the enzymes degrading high molecular weight polysaccharides through hydrolysis. The hydrolysis product is called glucan, which is a linear polysaccharide comprising up to 1200 monomeric glucose residues linked by glycosidic bonds. Catalysis of glycosidic bonds in polysaccharides is main function of glucanase. This function is no highly specific, andsubstrate specificity of the enzymes is based mainly on the bond types and α- or β-configuration

[0033] . β-1,3-Glucanases are able to destroy the cell wall of some fungi and to cleave the fragments exhibiting immunoregulatory activities (elicitors and suppressors)

[0034] , with the highest activity achieved at pH 4.0 and 80 °C [DOI: 10.1111 / j.1750-3841.2007.00549.x]. Beta-glucosidase, a group of glycosyl hydrolases commonly found in fungi, plants and bacteria, have identical structures and sequences. β-glucosidases producing monosaccharides from cellulose-based oligosaccharides play a key role in the biomass hydrolysis. The highest activity is achieved at 85 °C, pH 4.5–7.0 [Singhania RR, Patel AK, Sukumaran RK, Larroche C, Pandey A. Role and significance of beta-glucosidases in the hydrolysis of cellulose for bioethanol production. Bioresour Technol. 2013 Jan;127:500-7. DOI:10.1016 / j.biortech.2012.09.012]. According to classification based on substrate specificity β-glucosidases fall into three groups: aryl-β-glucosidase cleaving predominantly aryl glucosides; cellobiases involved in disaccharide cellobiose transformation to glucose; and glucosidases, which are most abundant and demonstrate extensive substrate-specific activities toward a broad range of substrates

[0035] . Different environmental conditions required for optimal enzyme activity could be the main factor limiting the early development of such enzymatic system. Some formulations of anti-dandruff shampoos are known from

[0037] . The authorsreported that Malassezia species are common, clinically relevant, and lipid-dependent yeasts ofhumans. They are also the leading causes of the dandruff problem of humans, and the azoles are used primarily in their topical and systemic treatment. Resistance to azoles is an emergingproblem among Malassezia spp., which limits the use of azoles and other agents in treatment.The efficacy of various combinations of piroctone olamine and climbazole is highly important.The disclosed study included nine formulations, where each formulation was prepared from different concentrations of piroctone olamine and climbazole and both. All formulations contained the same ingredients: water, surfactants, hair conditioning agents, andpreservatives. Malassezia furfur CBS1878, Malassezia globosa CBS7874, and Malasseziasympodialis CBS9570 were tested for antifungal susceptibility of each formulation by agardiffusion method. Sizes of the inhibition zones were compared with standard medical shampoo containing 2% ketoconazole, and the data were analyzed by Dunnett's multiple-comparison test.For all Malassezia sp. strains, climbazole 0.5% and piroctone olamine / climbazole (0.1% / 0.1%and 0.1% / 0.5%) combinations were found to have the same effect as the medical shampoo containing 2% ketoconazole. Piroctone olamine / climbazole 1.0% / 0.1% formulation showed thesame efficacy as 2% ketoconazole on M. furfur and M. sympodialis, while 0.1% / 0.5%formulation was effective only against M. furfur. For M. globosa, none of the formulationstested was as effective as ketoconazole. The use of chitosanase in preparation of formulations intended for treatment orprevention of skin diseases caused by Malassezia spp. is disclosed in Chinese patent application

[0038] . The authors provided the method of preparation of chitosanase composite gel, comprising the following steps: 1) dissolution of chitosanase in acetic acid-sodium acetate buffer; 2) dissolution of hyaluronic acid in acetic acid-sodium acetate buffer; 3) slow addition of chitosanase solution to hyaluronic acid solution with stirring to obtain the resultant product. However, there remains a need in highly effective products, which will be able todestroy the fungi of Malassezia spp. causing dandruff.SUBSTANCE OF THE INVENTION The invention is set out in the appended claims. The following embodiments show thesubstance of the invention. It will be understood by those skilled in the art that possible small variations of the listed embodiments are nevertheless also within the scope of the invention.1. The use of combination of two enzymes selected from chitinase and chitosanase toprepare a therapeutic anti-dandruff head-washing shampoo.2. The use of combination of two enzymes selected from chitinase and β-glucosidase toprepare a therapeutic anti-dandruff head-washing shampoo.3. The use of combination of two enzymes selected from chitinase and β-glucanase toprepare a therapeutic anti-dandruff head-washing shampoo.4. The use of combination of two enzymes selected from chitinase and β-mannanase toprepare a therapeutic anti-dandruff head-washing shampoo.5. The use of combination of two enzymes selected from chitinase and cellulase to preparea therapeutic anti-dandruff head-washing shampoo.6. The use according to any one of embodiments 1 to 5, wherein chitinase and the secondenzyme of said combination are taken at a mass ratio 1:(0.5-1.5), preferably 1:(0.7-1.3), more preferably 1:(0.9-1.1), even more preferably 1:1.7. The use of chitinase in combination with two or more enzymes selected from the groupcomprising chitosanase, β-glucosidase, β-glucanase, β-mannanase and cellulase, to prepare a therapeutic anti-dandruff head-washing shampoo.8. The use according to embodiment 7, wherein chitinase and the second enzyme of saidcombination are taken at a mass ratio 1:(0.5-1.5), preferably 1:(0.7-1.3), more preferably 1:(0.9- 1.1), even more preferably 1:1.9. The use according to embodiment 7, wherein chitinase, the second enzyme and the thirdenzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5), preferably 1:(0.7- 1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1), even more preferably 1:1:1.10. The use according to embodiment 7, wherein chitinase, the second enzyme, the thirdenzyme, and the fourth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5- 1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9- 1.1):(0.9-1.1), even more preferably 1:1:1:1.11. The use according to embodiment 7, wherein chitinase, the second enzyme, the thirdenzyme, the fourth enzyme, and the fifth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9-1.1), even more preferably 1:1:1:1:1.12. The use according to embodiment 7, wherein chitinase, the second enzyme, the thirdenzyme, the fourth enzyme, the fifth enzyme, and the sixth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5), preferably 1:(0.7- 1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9- 1.1):(0.9-1.1), even more preferably 1:1:1:1:1:1.13. The use of chitosanase in combination with two or more enzymes selected from thegroup comprising chitinase, β-glucosidase, β-glucanase, β-mannanase, and cellulase to prepare a therapeutic anti-dandruff head-washing shampoo.14. The use according to embodiment 13, wherein chitosanase and the second enzyme ofsaid combination are taken at a mass ratio 1:(0.5-1.5), preferably 1:(0.7-1.3), more preferably 1:(0.9-1.1), even more preferably 1:1.15. The use according to embodiment 13, wherein chitosanase, the second enzyme and thethird enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1), even more preferably 1:1:1.16. The use according to embodiment 13, wherein chitosanase, the second enzyme, the thirdenzyme and the fourth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5- 1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9- 1.1):(0.9-1.1), even more preferably 1:1:1:1.17. The use according to embodiment 13, wherein chitosanase, the second enzyme, the thirdenzyme, the fourth enzyme и the fifth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3),more preferably 1:(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9-1.1), even more preferably 1:1:1:1:1.18. The use according to embodiment 13, wherein chitosanase, the second enzyme, the thirdenzyme, the fourth enzyme, the fifth enzyme и the sixth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7- 1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9- 1.1), even more preferably 1:1:1:1:1:1.19. The use of cellulase in combination with two or more enzymes selected from the groupcomprising chitosanase, chitinase, β-glucosidase, β-glucanase, and β-mannanase, to prepare a therapeutic anti-dandruff head-washing shampoo.20. The use according to embodiment 19, wherein cellulase and the second enzyme of saidcombination are taken at a mass ratio 1:(0.5-1.5), preferably 1:(0.7-1.3), more preferably 1:(0.9- 1.1), even more preferably 1:1.21. The use according to embodiment 19, wherein cellulase, the second enzyme and thethird enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5), preferably1:(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1), even more preferably 1:1:1.22. The use according to embodiment 19, wherein cellulase, the second enzyme, the thirdenzyme and the fourth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5- 1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9- 1.1):(0.9-1.1), even more preferably 1:1:1:1.23. The use according to embodiment 19, wherein cellulase, the second enzyme, the thirdenzyme, the fourth enzyme и the fifth enzyme of said combination are taken at a mass ratio 1:(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9-1.1), even more preferably 1:1:1:1:1.24. The use according to embodiment 19, wherein cellulase, the second enzyme, the thirdenzyme, the fourth enzyme, the fifth enzyme и the sixth enzyme of said combination are takenat a mass ratio 1:(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9- 1.1), even more preferably 1:1:1:1:1:1.25. The use according to any one of embodiments 1 to 24, wherein the dandruff is causedby the presence of at least one of M. furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta,M. slooffiae and / or M. pachydermatis on scalp.26. The use according to embodiment 25, wherein the dandruff is caused by the presence ofM. furfur on scalp.27. The use according to embodiment 25, wherein the dandruff is caused by the presence ofM. sympodialis on scalp.28. The use according to embodiment 25, wherein the dandruff is caused by the presence ofM. obtuse on scalp.29. The use according to embodiment 25, wherein the dandruff is caused by the presence ofM. globose on scalp.30. The use according to embodiment 25, wherein the dandruff is caused by the presence ofM. restricta on scalp.31. The use according to embodiment 25, wherein the dandruff is caused by the presence ofM. slooffiae on scalp.32. The use according to embodiment 25, wherein the dandruff is caused by the presence ofM. pachydermatis on scalp.33. The use according to any one of the embodiments 1 to 24, wherein the dandruff is causedby the presence of any two of M. furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta,M. slooffiae and / or M. pachydermatis on scalp.34. The use according to any one of the embodiments 1 to 24, wherein the dandruff is causedby the presence of any three of M. furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta,M. slooffiae and / or M. pachydermatis on scalp.35. The use according to any one of the embodiments 1 to 24, wherein the dandruff is causedby the presence of any four of M. furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta,M. slooffiae and / or M. pachydermatis on scalp.36. The use according to any one of the embodiments 1 to 24, wherein the dandruff is causedby the presence of any five of M. furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta,M. slooffiae and / or M. pachydermatis on scalp.37. The use according to any one of the embodiments 1 to 24, wherein the dandruff is causedby the presence of any six of M. furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta,M. slooffiae and / or M. pachydermatis on scalp.38. The use according to any one of the embodiments 1 to 24, wherein the dandruff is causedby the presence of M. furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiaeand M. pachydermatis on scalp.DETAILED DESCRIPTION OF THE INVENTION The present invention is related to the use of combination of two enzymes selected fromchitinase and chitosanase to prepare a therapeutic anti-dandruff head-washing shampoo. The present invention is also related to the use of combination of two enzymes selected from chitinase and β-glucosidase to prepare a therapeutic anti-dandruff head-washing shampoo. The present invention is also related to the use of combination of two enzymes selected from chitinase and β-glucanase to prepare a therapeutic anti-dandruff head-washing shampoo. The present invention is also related to the use of combination of two enzymes selected from chitinase and β-mannanase to prepare a therapeutic anti-dandruff head-washing shampoo. The present invention is also related to the use of combination of two enzymes selected from chitinase and cellulase to prepare a therapeutic anti-dandruff head-washing shampoo. The present invention is also related to the use of chitinase in combination with two or more enzymes selected from the group comprising chitosanase, β-glucosidase, β-glucanase, β- mannanase, and cellulase to prepare a therapeutic anti-dandruff head-washing shampoo. The present invention is also related to the use of chitosanase in combination with two or more enzymes selected from the group comprising chitinase, β-glucosidase, β-glucanase, β- mannanase, and cellulase to prepare a therapeutic anti-dandruff head-washing shampoo. The present invention is also related to the use of cellulase in combination with two or more enzymes selected from the group comprising chitosanase, chitinase, β-glucosidase, β- glucanase, and β-mannanase to prepare a therapeutic anti-dandruff head-washing shampoo. The dandruff can be caused by the presence on scalp of at least any one of M. furfur,M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and / or M. pachydermatis.More particularly, the dandruff can be caused by the presence of M. furfur on scalp.More particularly, the dandruff can be caused by the presence of M. sympodialis on scalp. Moreparticularly, the dandruff can be caused by the presence of M. obtuse on scalp. Moreparticularly, the dandruff can be caused by the presence of M. globose on scalp. Moreparticularly, the dandruff can be caused by the presence of M. restricta on scalp. Moreparticularly, the dandruff can be caused by the presence of M. slooffiae on scalp. Moreparticularly, the dandruff can be caused by the presence of M. pachydermatis on scalp.More particularly, the dandruff can be caused by the presence of any two of M. furfur,M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and / or M. pachydermatis onscalp. More particularly, the dandruff can be caused by the presence of any three of M. furfur,M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and / or M. pachydermatis onscalp. More particularly, the dandruff can be caused by the presence of any four of M. furfur,M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and / or M. pachydermatis onscalp. More particularly, the dandruff can be caused by the presence of any five of M. furfur,M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and / or M. pachydermatis.More particularly, the dandruff can be caused by the presence of any six of M. furfur,M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and / or M. pachydermatis.More particularly, the dandruff can be caused by the presence of M. furfur, M.sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae и M. pachydermatis on scalp.In accordance with invention, chitinase, or chitosanase, or cellulase, and the second enzyme, and / or the third enzyme, and / or the fourth enzyme, and / or the fifth enzyme and / or thesixth enzyme (if present in the embodiment of combination) can be taken at a mass ratio 1:(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5), preferably 1:(0.7-1.3):(0.7-1.3):(0.7-1.3):(0.7- 1.3):(0.7-1.3), more preferably 1:(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9-1.1):(0.9-1.1), even more preferably 1:1:1:1:1:1 (depending on the number of taken enzymes). In accordance with invention, the enzyme concentration can be in the range from 0.05to 5 % by mass including 0.05, 0.1. 0.125, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0. 1.2, 1.4,1.6, 1.8, 2,0.2.2, 2.4, 2.6, 2.8, 3.0.3.2, 3.4, 3.6, 3.8, 4.0.4.2, 4.4, 4.6, 4.8, 5.0, and in any range between the listed values. EXPERIMENT Commercially available products containing climbazole, piroctone olamine, selenium sulfide, zinc pyrithione and the enzymes are listed in Tables 1 and 2. Table 1. Commercially available products No. Ingredient CAS Number Origin Supplier1 Climbazole 38083-17-9 Synthetic Symrise, GermanyCrinipan® AD 2Piroctone olamine 68890-66-4 Synthetic COSROMA, ChinaCosroma® OCT 3Selenium sulfide 7488-56-4 Synthetic COSROMA, ChinaCosroma® SS20 4Zinc pyrithione 13463-41-7 Synthetic Salicylates and Chemicals, Indiareedtyr,t. ra sdt e,.o C ren L iloi,.o udL Y,.nsa nip PC aninIoan eerkro h piu xnhc hC noC ihC p C GiW,SaaetS u X ndthoinoroiL S B u S Gun W U etafetafetafnoelulseulseus e itmrererisyzmum isyzmummm iyz ui yeztameyztameyztaopn n EesnE ense n EWnWnWmo%0gna%0gaEn%ga% % 0 0E% 9 % 2E% 9 % 2 C 3M3M8 M 1 8 8 9 %0 %0 % 7 729rew ec olw d o wd d dnle lrler o piui iq u q u ary e y eaehi iqis dpiwhs dw wollnlnln pno ino lew w w A wpo wpy rtorororroh B B B B Bgi2L1seseseseses ss s sea a as sd da a aid d d dmess siosiosisisistc co o o osaly yc c c cl lylylylylyCsG G G G G Ge 1.1.1.1 1 1vit2a.3 2.3 2. .32. .32. .32.3vonnrieb 38-3- 3 83-rom -fu60-024-1-2-24545seNS10 0-73 - --1 10288 m05 20102yA9zC1526 9 973nedetageesese e e as sae saitmasn n aeyzitandi ssalnaisaot cuoculn lnvnhilgule anIE Ch.C -β g- C m-2β βelba.oN 1 2 3 4 5 6 T Test Microorganisms and Growth Conditions The fungal strains: M. furfur CBS 1878, M. restricta CBS 7877, M. globosa CBS 7966were purchased from Westerdijk institute, Utrecht, The Netherlands. The strains werecultured in the The Sabouraud dextrose agar (SDA) agar and then incubated in the CHROMagar Malassezia® with Tween-40 and Glycerol for visible growth at 37 °C for 72 h. The inoculum was diluted and cells were counted in a Neubauer chamber to reach desirable inoculum concentrations 1.0 × 106 CFU / mL All microbiology work was done inside a microbiology safety cabinet (Faster, Italy). Antifungal Screening by Determining the Log10CFU Reduction The Log10CFU reduction in fungi in the presence of antifungal substances was used to evaluate the inhibitory effect of the tested substance on a population of M. furfur, M. globosa,M. restricta by exposure to the substance through quantitate evaluation of viable total colonycounts. The final concentrations of substances were 5.00, 3.00, 2.00, 1.00, 0.50, 0.25, 0.125 and 0.05 weight % prepared in water with 0.3% Polysorbate 80. Antifungal drugs such as climbazole, piroctone olamine, zinc pyrithione and selenium sulfide, recommended for the treatment of dandruff, were used as controls. Then, 1 mL of microorganisms at a 1.0 × 106 CFU / mL concentration was cultured with 9 mL of each sample concentration. The experimental procedure consisted of the substance incubation with a known suspension of M.furfur, M. restricta and M. globosa at 37 °C for 1 hour as the average time for a possibleeffect of ingrediets for the treatment of dandruff. The incubation was performed on substrate culture media (Mueller Hinton broth). After the incubation period, the viable fungi population was monitored by counting the viable cells on an agar plate (CHROMagar Malassezia). The suspension of the microorganism inoculum without substance was used as a negative control. The experiments were carried out in triplicate. The result was expressed in a decimal logarithm of the reduction in colony forming units per mL (log10CFU / mL) (Table 3) and thenconverted to anti-fungal efficacy indicated in percentage of inhibition (Table 4). Inhibitoryactivity of the enzymes against Malassezia spp. was confirmed by stability results at temperatures from 4 to 40 °C. The pH of the medium was typical of hair products and was between 4 and 8. %0 5 0.8.5 8.5 8.5 8.495 8.26425 8.5 8 5 8 5 85 815 89 5 5 > 5 > 5 >5 >4.04.05 >3.05.00.03.05.>5.> 5.> 5.>5 >8. .05 >9.0 %0 0.4 5 31.8.55235693255 5 20795 1 58.> 58.>5 >4.04.8.05 >1.03.00.02.8.058.8.>5 > 5 >5.12.17.06.38.0 %0 3 5 555 5 9 5 5 0.19.8.8.8.0 5 > 5 >5 >2.7 02.8.0 05 >1.5 02.1 00.913 0.00.8.8.6 15 > 5 >2.0 11.6 17.3 00.5 27.0 % 5 9 5 55 88.8.8.9 145 18.6 016 21345 8.5 8.99192noi.t0.0 5 > 5 >5 >.0.05 >.0.00.01.08.05 > 5 >8.09.07.01.16.0cude%5 5 552395751255 5 6101R 2.08.8.0 58.> 58.>5 >1.01.07.10.01.00.1.7.8.58.58.9.7.9.3 5.U 0 0 0 > > 0 0 0 0 0 F C01% a 52 2goL.7 3 36824291711 2 32953 D1eS07.06.18.13.10.00.00.10.00.00.00.06.07.15.25.08.06.08.04.0ht±nga%i5 0n.1iM,06.9 5ne01.1 14.7 18.4 00.1 00.7 07.1 00.5 00.0 00.6 00.1 05.5 03.5 13.9 24.6 07.2 06.8 06.2 03.0mrUetFeCed0vil41taor1fo gsoge tn otlL Ncuseat eR.cisaes)3 rt×0.)nilt an) )1:) 1e se1 1:)ihitbr i 1:1:1:1 a.61 1:ch)1 1 oitTM6 , 9 n1+c+ 1:oit oi ar(oita877 oiStaoi81Br(teaser( ades1atoa er(eisaditr(r(saese adesaSC ia sasaoc s r(adsaisn BsCo n n r basaculocegsisnaocacu -ulalocnululfole r gnie o udietiu g-ulu nag-g- hlgβ+β le lβ βf.) m . M M,Lalfln e uoiCese - βe) +g-m-e)C β β + +( 7m / elo es htes+aesadisa+sa1:sa1:+ e+ + esess7 n 8Uoi7Fza n miresanbosns naesesna1:n1:esesanantuiypanas aac onalann1 as1 saananasasarSCt6 mcnSBiC01loelciCriPeSntiihotniihtiuhlcunaglgmullZ C C C-β-β-β eitniaChmoio t C-β atiointitiiti iti oti otir(h Car(h ChChChChC .oN 1 2 34 5 6 7 8 901112131415161718191 % 0 0.0 0.0 0.0 0.8.2 0 0.141 2 0 0 0 0000 0 0 0 2003 0 0.00 00 00 00 38.6 7 02. .6 0 2 21.7 05. . .2 00 0.00 .0 0.0 06..0 402.0 9 5 1 1 1 1 1 5 1 5 1 111 1 818 % 500 0 60. 0.0.9 0 94.0.6 7 1 7 5 6 0 004 0.0. 09 0 1 8 7 0 0. .200 0.1 3 0.0.93. .0 0 0.09.67.32.39.97.5 3 90101 01 6 6 01 3 5 7 4 01 01019 9 8 9 8 n %oiti100 0 0 0 .20. 0.0.2 6 2 90.1.4 4 6 207 7.0. 0.2 6 6 0 8 4 0 0bi . 00 0.4.6 01.32. .5 0 00 .41.29.20.94.2 1 h8ni 80101 01 4 4 0124 4 3 9 01019 9 8 9 8 .p ps0 0 %ai6020. 0.0.8 3 2 0 90.4 26.1 2 5 0 0.0 0.1 6 7 6 1 5. z . 00 0.5.6 0.88.0.66.0 03.78.96.06.31.nes7800 0 0313 3580 0 6oi0sa 11 1 3 2 1 2 1 1 8 8 8 9 7tibilahnMi%f3000p0.0 0 5 5 8 5 5 53 30 0 0 0 9 3 1 6 5.5o 4..00.08.1.3.7.2.4. .4. . .2.8.1.7.4.ps2.0 %480101 0 3 1 2 62 890123 3 22800 0 1 0 6 1 8 78 08 78 07aizessa%5 2 0 5 4 1 5 8 3 5 622 6 77.7 9 7 0 0la2.6.5.7.1.3M1.0..387981.1. 91.8.0.93.9.5.9.9.9 59 61 5 19 4 81.2615789 9 07 48 97 58 2651f0otnec% 5 4 6 5 7 16.7 6 4 3 166 1 8 4 2 6 2 1 2 3 4re5.5.3.66.2. . .5.2.9.3.6.5.2.6.0.2.8.P.0.0 7 9 9801 3 38 2 01 1 219659 99 86 28 67 97 154elb )a1:) T1:11:(e1:s1(aneisti ahnictih ) +c) ) )e+1:)1:11) (1:1:1(1:sades 1( :1(es1(ee1(is ad)1seasaocis:eseadsao1(adsaisn n nulgci n ou es s ancaceasac-β lgalocn ululg nnie o dietiulg + -βull ul ag- β-βoim t n h -eg-m- aalflo Ce eβ e+ c β β + +ro uiestel+ esasnoz es htiasaesesesre an esadina+e n an+e +e +e ananecan b o m n mtcuiysaaonep cnissan ta sonesiotnitciulcul naasllaanaunis stna tastasta a aonininistostotoill nhiggml imi i i i i iC CriPeSiZ Chh C C -β-β-β eChC -β hChChChChChC LITERATURE 1. Byrd, A.L.; Belkaid, Y.; Segre, J.A. The human skin microbiome \\ Nat. Rev.Microbiol. 2018, 16, 143–155.2. Oh, J., Byrd, A. L., Deming, C., Conlan, S., Kong, H. H., Segre, J. A., et al.(2014). Biogeography and individuality shape function in the human skin metagenome\\ Nature 514, 59–64.3. Brandwein, M., Steinberg, D., and Meshner, S. (2016). Microbial biofilms andthe human skin microbiome \\ NPJ Biofilms Microbiomes 2:3.4. Rinaldi, F.; Pinto, D.; Marzani, B.; Rucco, M.; Sorbellini, E.; Giuliani, G.Human microbiome: What’s new in scalp diseases \\ J. Transl. Sci. 2018, 4, 1–4.5. Pinto, D.; Sorbellini, E.; Marzani, B.; Rucco, M.; Giuliani, G.; Rinaldi, F. Scalpbacterial shift in Alopecia areata \\ PLoS ONE 2019, 14.6. Pinto, D.; Calabrese, F.M.; De Angelis, M.; Celano, G.; Giuliani, G.; Gobbetti,M.; Rinaldi, F. Predictive Metagenomic Profiling, Urine Metabolomics, and Human MarkerGene Expression as an Integrated Approach to Study Alopecia Areata \\ Front. Cell. Infect.Microbiol. 2020, 10, 146.7. Nakatsuji, T.; Chiang, H.I.; Jiang, S.; Nagarajan, H.; Zengler, K.; Gallo, R.L.The microbiome extends to subepidermal compartments of normal skin \\ Nat.Commun. 2013, 4, 1431.8. Saxena, R.; Mittal, P.; Clavaud, C.; Dhakan, D.B.; Hegde, P.; Veeranagaiah,M.M.; Saha, S.; Souverain, L.; Roy, N.; Breton, L.; et al. Comparison of Healthy and DandruffScalp Microbiome Reveals the Role of Commensals in Scalp Health \\ Front. Cell. Infect.Microbiol. 2018, 8, 346.9. Grimshaw, S.G.; Smith, A.M.; Arnold, D.S.; Xu, E.; Hoptroff, M.; Murphy, B.The diversity and abundance of fungi and bacteria on the healthy and dandruff affected humanscalp \\ PLoS ONE 2019, 14.10. Clavaud, C.; Jourdain, R.; Bar-Hen, A.; Tichit, M.; Bouchier, C.; Pouradier, F.;El Rawadi, C.; Guillot, J.; Ménard-Szczebara, F.; Breton, L.; et al. Dandruff is associated withdisequilibrium in the proportion of the major bacterial and fungal populations colonizing thescalp \\ PLoS ONE 2013, 8.11. Wang, L.; Clavaud, C.; Bar-Hen, A.; Cui, M.; Gao, J.; Liu, Y.; Liu, C.;Shibagaki, N.; Guéniche, A.; Jourdain, R.; et al. Characterization of the major bacterial-fungal populations colonizing dandruff scalps in Shanghai, China, shows microbial disequilibrium \\Exp. Dermatol. 2015, 24, 398–400.12. Soares, R.C.; Camargo-Penna, P.H.; de Moraes, V.C.S.; De Vecchi, R.; Clavaud,C.; Breton, L.; Braz, A.S.K.; Paulino, L.C. Dysbiotic bacterial and fungal communities notrestricted to clinically affected skin sites in dandruff \\ Front. Cell. Infect. Microbiol. 2020, 6,157. 13. Xu, Z.; Wang, Z.; Yuan, C.; Liu, X.; Yang, F.; Wang, T.; Wang, J.; Manabe, K.;Qin, O.; Wang, X.; et al. Dandruff is associated with the conjoined interactions between hostand microorganisms \\ Sci. Rep. 2016, 6, 24877.14. Rinaldi, F.; Trink, A.; Papale, A.; Giuliani, G.; Pinto, D. Clinical Translation ofMicrobiome Research in Alopecia Areata: A New Perspective? \\ Cosmetics. 2022, 9, 55.15. Lin, Q., Panchamukhi, A., Li, P. et al. Malassezia and Staphylococcus dominatescalp microbiome for seborrheic dermatitis \\ Bioprocess Biosyst Eng 44, 965–975 (2021).16. Schommer N.N., Gallo R.L. Structure and function of the human skinmicrobiome \\ Trends Microbiol. 2013; 21(12), 660-8.17. Narshana M and Ravikumar P: An overview of dandruff and novel formulationsas a treatment strategy \\ Int J Pharm Sci & Res. 2018; 9(2): 417-31.18. Gilbertson K, Jarrett R, Bayliss SJ and Berk DR: Scalp discoloration fromselenium sulfide shampoo: a case series and review of the literature \\ Pediatric dermatology2012; 29(1): 84-8. 19. Couto FM, Nascimento SC, Júnior SF, Silva VK, Leal AF and Neves RP:Antifungal activity of the piroctoneolamine in experimental intra-abdominal candidiasis \\ Springer Plus 2016; 5(1): 468. 20. Mangion, S.E.; Holmes, A.M.; Roberts, M.S. Targeted Delivery of ZincPyrithione to Skin Epithelia \\ Int. J. Mol. Sci. 2021, 22, 9730.21. Israa A. Al-Temimay1, Alaa M. Hasan. Isolation and identification of fungi fromthe droppings of some poultry and some detergents effect on some of them \\ Iraqi Journal ofScience, 2016, Vol.57, No.4B, pp: 4362 -2640. 22. Shibata, N., Saitoh, T., Tadokoro, Y., & Okawa, Y. (2009). The cell wallgalactomannan antigen from Malassezia furfur and Malassezia pachydermatis contains -1,6- linked linear galactofuranosyl residues and its detection has diagnostic potential \\ Microbiology, 155(10), 3420–3429. 23. Ravindra Pal Singh, Sivasubramanian Rajarammohan, Raksha Thakur &Mohsin Hassan. Linear and branched β-Glucans degrading enzymes from versatile Bacteroidesuniformis JCM 13288T and their roles in cooperation with gut bacteria \\ Gut Microbes, 12:1,(2020).24. Sakamoto, Y., Nakade, K., Sato, S., Yoshida, K., Miyazaki, K., Natsume, S., &Konno, N. (2017). Lentinula edodes Genome Survey and Postharvest Transcriptome Analysis\\ Applied and Environmental Microbiology, 83(10).25. Hua Zhang, Steven H. Neau. In vitro degradation of chitosan by a commercialenzyme preparation: effect of molecular weight and degree of deacetylation \\ Biomaterials, V.22, № 12, 2001, Pages 1653-1658. 26. Hamid R, Khan MA, Ahmad M, Ahmad MM, Abdin MZ, Musarrat J, Javed S.Chitinases: An update \\ J Pharm Bioallied Sci. 2013 Jan;5(1):21-9.27. Nidheesh Thadathil, Suresh Puthanveetil Velappan. Recent developments inchitosanase research and its biotechnological applications: A review \\ Food Chemistry.Volume 150, 2014, Pages 392-399.28. Guého E, Midgley G, Guillot J. The genus Malassezia with description of fournew species. Antonie Van Leeuwenhoek.1996, 69(4):337-55. 29. Anita Singh, Somvir Bajar, Arti Devi, Deepak Pant. An overview on the recentdevelopments in fungal cellulase production and their industrial applications \\ BioresourceTechnology Reports, Volume 14, 2021, 100652. 30. Yu Cao, Huimin Tan. Effects of cellulase on the modification of cellulose \\Carbohydrate Research, Volume 337, Issue 14, 2002, Pages 1291-1296. 31. Barry V. McCleary. β-d-Mannanase \\ Methods in Enzymology, AcademicPress, Volume 160, 1988, Pages 596-610. 32. Abosereh, NivienA & Ismail, SihamA & Khattab, OmK.H & Nour, ShaimaaA& Abo-Elnasr, AmanyA & Hashem, AmalM. (2019). Genetic improvement of fungal β-mannanase and its molecular differentiation \\ Egyptian Pharmaceutical Journal. 18. 403.33. Antoni Planas. Bacterial 1,3-1,4-β-glucanases: structure, function and proteinengineering \\ Biochimica et Biophysica Acta (BBA) - Protein Structure and MolecularEnzymology, Volume 1543, Issue 2, 2000, Pages 361-382. 34. V G Dzhavakhiya, O.L. Ozeretskovskaya, S.V. Zinovyeva. Chapter 10 -Immune response. In Studies in Plant Science \\ Comprehensive and MolecularPhytopathology, Elsevier, 2007, Pages 265-314. 35. Srivastava, N.; Rathour, R.; Jha, S.; Pandey, K.; Srivastava, M.; Thakur, V.K.;Sengar, R.S.; Gupta, V.K.; Mazumder, P.B.; Khan, A.F.; et al. Microbial Beta Glucosidase Enzymes: Recent Advances in Biomass Conversation for Biofuels Application. Biomolecules 2019, 9, 220.36. Thomas Stalhberger Catherine Simenel§, Ce´ cile Clavaud, Vincent G. H.Eijsink, Roland Jourdain, Muriel Delepierre, Jean-Paul Latge, Lionel Breton and Thierry Fontaine. Chemical organization of the cell wall polysaccharide core of Malassezia restricta \\J Biol Chem. 2014 May 2;289(18):12647-56. doi: 10.1074 / jbc.M113.547034. Epub 2014 Mar13. 37. Ergin C., Kurt O., Turkoglu M., Sevinc H., Akbaba G. Evaluation of novelcosmetic shampoo formulations against Malassezia species: Preliminary results of anti-dandruff shampoo formulations \\ Journal of Cosmetic Dermatology 202423:6 (2078-2083).38. CN115607656A·(BAIKUIRUI TIANJIN BIOTECHNOLOGY CO LTD) 2023-01-17.

Claims

CLAIMS1. The use of the following combination of enzymesa) chitinasein combination with at least one of the following enzymes:i) chitosanase;ii) β-glucanase;iii) β-glucosidase;iv) β-mannanase;v) cellulase;wherein said combination of chitinase and said further enzyme selected from i)-v) aretaken at a mass ratio 1.0 : 0.5-1.5, preferably 1.0 : 0.7-1.3, further preferably 1.0 : 0.9-1.1, even more preferably 1.0 : 1.0; orb) chitosanasein combination with at least one of the following enzymes:i) chitinase;ii) β-glucanase;iii) β-glucosidase;iv) β-mannanase;v) cellulase;wherein said combination of chitosanase and said further enzyme selected from i)-v) are taken at a mass ratio 1.0 : 0.5-1.5, preferably 1.0 : 0.7-1.3, further preferably 1.0 : 0.9-1.1, even more preferably 1.0 : 1.0;in the manufacture of a hair care and / or scalp care composition.

2. Non-medical use of a hair care and / or scalp care composition, said compositioncomprising the following combination of enzymes a) chitinasein combination with at least one of the following enzymes:i) chitosanase;ii) β-glucanase;iii) β-glucosidase;iv) β-mannanase;v) cellulase;wherein said combination of chitinase and said further enzyme selected from i)-v) are taken at a mass ratio 1.0 : 0.5-1.5, preferably 1.0 : 0.7-1.3, further preferably 1.0 : 0.9-1.1, even more preferably 1.0 : 1.0; orb) chitosanasein combination with at least one of the following enzymes:i) chitinase;ii) β-glucanase;iii) β-glucosidase;iv) β-mannanase;v) cellulase;wherein said combination of chitosanase and said further enzyme selected from i)-v) are taken at a mass ratio 1.0 : 0.5-1.5, preferably 1.0 : 0.7-1.3, further preferably 1.0 : 0.9-1.1, even more preferably 1.0 : 1.0; for application on a subject’s hair and / or scalp.

3. The non-medical use of claim 2, wherein said composition is for the treatment of thehair and / or scalp of a subject suffering from dandruff.

4. The non-medical use of claim 3, wherein said dandruff is caused by fungi of theMalassezia species.

5. The non-medical use of claim 4, wherein said Malassezia species comprise M. furfur,M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and M.pachydermatis, preferably M. furfur, M. globosa, M. restricta, further preferably M.furfur CBS 1878, M. restricta CBS 7877, M. globosa CBS 7966.

6. A hair care and / or scalp care composition, said composition comprising the followingcombination of enzymes a) chitinasein combination with at least one of the following enzymes:i) chitosanase, preferably further comprising β-glucosidase;ii) β-glucanase;iii) β-glucosidase, preferably further comprising β-mannanase;iv) β-mannanase;v) cellulase;wherein said combination of chitinase and said further enzyme selected from i)-v) are taken at a mass ratio 1.0 : 0.5-1.5, preferably 1.0 : 0.7-1.3, further preferably 1.0 : 0.9-1.1, even more preferably 1.0 : 1.0; orb) chitosanase in combination with at least one of the following enzymes:i) chitinase;ii) β-glucanase;iii) β-glucosidase;iv) β-mannanase;v) cellulase;wherein said combination of chitosanase and said further enzyme selected from i)-v) are taken at a mass ratio 1.0 : 0.5-1.5, preferably 1.0 : 0.7-1.3, further preferably 1.0 : 0.9- 1.1, even more preferably 1.0 : 1.0; for use in the treatment of dandruff and / or a disease selected from Pityriasis capitis andPityriasis simplex capillitia.

7. The composition for use of claim 6, wherein said dandruff and / or disease is caused byfungi of the Malassezia species.

8. The composition for use of claim 7, wherein said Malassezia species comprise M.furfur, M. sympodialis, M. obtusa, M. globosa, M. restricta, M. slooffiae and M.pachydermatis, preferably M. furfur, M. globosa, M. restricta, further preferably M.furfur CBS 1878, M. restricta CBS 7877, M. globosa CBS 7966.

9. The use or composition for use of any of the preceding claims, wherein saidcomposition comprises any of the combination of said enzymes, including one of the following enzyme combinations: i) chitinase and chitosanase;ii) chitinase and β-glucanase;iii) chitinase and β-glucosidase;iv) chitinase and β-mannanase;v) chitinase and cellulase;vi) chitosanase and β-glucanase;vii) chitosanase and β-glucosidase;viii) chitosanase and β-mannanase;ix) chitosanase and cellulase;x) chitinase, β-glucanase and β-glucosidase;xi) chitinase, β-glucanase and β-mannanase;xii) chitinase, β-glucanase and cellulase;xiii) chitosanase, β-glucanase and β-glucosidase;xiv) chitosanase, β-glucanase and β-mannanase;xv) chitosanase, β-glucanase and cellulase;xvi) chitinase, chitosanase and β-glucanase;xvii) chitinase, chitosanase and β-glucosidase;xviii) chitinase, chitosanase and β-mannanase;xix) chitinase, chitosanase and cellulase;xx) chitinase, chitosanase, β-glucanase and β-glucosidase;xxi) chitinase, chitosanase, β-glucanase and β-mannanase;xxii) chitinase, chitosanase, β-glucanase and cellulase;xxiii) chitinase, chitosanase, β-glucanase, β-glucosidase and β-mannanase;xxiv) chitinase, chitosanase, β-glucanase, β-glucosidase and cellulase;xxv) chitinase, chitosanase, β-glucanase, β-glucosidase, β-mannanase and cellulase.

10. The use or composition for use of any of the preceding claims,said chitinase having the CAS 9001-06-3 registration number; said chitosanase having the CAS 51570-20-8 registration number;said β-glucanase having the CAS 62213-14-3 registration number;said β-glucosidase having the CAS 9001-22-3 registration number;said β-mannanase having the CAS 37288-54-3 registration number; said cellulase having the CAS 9012-54-8 registration number.

11. The use or composition for use of any of the preceding claims, wherein saidcomposition is formulated for application on a subject’s hair and / or scalp.

12. The use or composition for use of claim 11, wherein said composition is a formulationselected from the following: liquid, aerosol, spray, foam, suspension, solution, tincture, cream, paste, lotion, ointment, gel, balsam.

3. The use or composition for use of claim 11 and / or 12, wherein, wherein saidformulations are scalp skin and / or hair adhesive formulations, including shower gel andshampoo for scalp and / or hair care.